ArticlePloS one2026
Elevated high sensitivity cardiac troponin T among men with HIV who use stimulants: A cross-sectional study of subclinical cardiovascular injury.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with HIV (PWH) experience elevated cardiovascular disease risk compared to people without HIV. Stimulant use may further increase subclinical myocardial injury among PWH, but data on cardiovascular biomarkers, including serum high-sensitivity cardiac troponin T (hs-cTnT) in this population is limited. This cross-sectional secondary analysis included 72 cisgender men with and without HIV enrolled in a South Florida cohort. Stimulant exposure was defined as any non-prescribed stimulant use in the past 3 months and/or a reactive urine toxicology screen, creating four HIV-by-stimulant use groups (i.e., HIV+Stim + , HIV+Stim-, HIV-Stim + , and HIV-Stim-). hs-cTnT was measured using a Roche high-sensitivity assay, with values below the limit of detection treated as undetectable. We used a two-part model (logistic for detectability; log-normal among participants with detectable hs-cTnT), adjusted for age and recent tobacco use, with sensitivity analyses adding renal function and cardiometabolic factors. After adjusting for age and recent tobacco use, HIV+Stim+ participants had higher odds of detectable hs-cTnT (aOR = 7.48, 95% CI: 1.25, 44.62) and higher estimated mean concentration of hs-cTnT (β = 0.51, p = 0.031, mean = 12) than the HIV-Stim- group. Exploratory analyses suggested a positive dose-response association between amphetamine metabolite levels and hs-cTnT (r(11) = 0.86, p < 0.0001). Co-occurring HIV and stimulant use were associated with higher hs-cTnT in this sample. However, given that hs-cTnT may reflect a range of acute, subacute, and chronic processes, and the small sample size and restricted generalizability, these findings should be interpreted as exploratory and hypothesis-generating and require confirmation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.